Skip to content
10-Q

Quarterly Report

Eledon Pharmaceuticals, Inc. ELDN

0001193125-26-221702

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 77.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 112.42M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$22.61M
Short Term Investments Q1 2026 · Mar 31, 2026 $104.94M
Short Term Investments Q1 2026 · Dec 31, 2025 $110.53M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $6.15M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $22.81M
Stockholders Equity Q1 2026 · Mar 31, 2026 $44.76M
Stockholders Equity Q1 2026 · Dec 31, 2025 $81.09M
Current Liabilities Q1 2026 · Mar 31, 2026 $13.46M
Current Liabilities Q1 2026 · Dec 31, 2025 $18.34M
Total Liabilities Q1 2026 · Mar 31, 2026 $46.21M
Total Liabilities Q1 2026 · Dec 31, 2025 $32.23M
Current Assets Q1 2026 · Mar 31, 2026 $113.57M
Current Assets Q1 2026 · Dec 31, 2025 $135.69M
Total Assets Q1 2026 · Mar 31, 2026 $146.67M
Total Assets Q1 2026 · Dec 31, 2025 $169.01M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.33
Eps Basic Q1 2026 · Mar 31, 2026 −$0.33
Sga Expense Q1 2026 · Mar 31, 2026 $3.98M
Rd Expense Q1 2026 · Mar 31, 2026 $17.2M
Net Income Q1 2026 · Mar 31, 2026 −$39.03M
Operating Income Q1 2026 · Mar 31, 2026 −$21.18M